Leadership

Meet Our Leadership Team

Our leadership team possesses deep and diverse industry knowledge, a passion for science and a shared commitment to help transform lives. Made up of our founding scientists, industry experts, Nobel Laureates and members of the National Academy of Sciences, we consistently push the boundaries of scientific excellence and discovery.

Our Founders

Leonard S. Schleifer, MD, PhD: Founder, President & Chief Executive Officer

Leonard S. Schleifer, MD, PhD

Founder, President and Chief Executive Officer

Leonard S. Schleifer, MD, PhD

Founder, President and Chief Executive Officer

Leonard S. Schleifer, MD, PhD, founded Regeneron in 1988, has been a Director and the company’s President and Chief Executive Officer since its inception. He served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Dr. Yancopoulos, has grown Regeneron from a tiny startup into a ~$50 billion market cap company, with a unique science-driven culture, successful drug discovery and development engine and nine FDA-approved medicines. Dr. Schleifer has been recognized as one of Barron’s Best CEOs and as an Ernst & Young Entrepreneur of the Year. He graduated from Cornell University and earned his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician, certified in Neurology by the American Board of Psychiatry and Neurology, and worked as a practicing neurologist before founding Regeneron.


Close

George D. Yancopoulos, MD, PhD: Founding Scientist, President & Chief Scientific Officer

George D. Yancopoulos, MD, PhD

Scientific Founder, President and Chief Scientific Officer

George D. Yancopoulos, MD, PhD

Scientific Founder, President and Chief Scientific Officer

George D. Yancopoulos, MD, PhD, has built and managed Regeneron alongside Dr. Schleifer since 1989. He is currently President and Chief Scientific Officer and has served on the board since 2001. Dr. Yancopoulos, along with key members of his team, is the principal inventor of Regeneron’s nine FDA-approved drugs and foundational technologies, including the TRAP technology, VelociGene® and VelocImmune®. He has been named an Ernst & Young Entrepreneur of the Year and has been pivotal in creating the science-driven, collaborative and highly productive R&D culture at Regeneron. This unique environment has earned the company widespread recognition, including repeatedly being named one of the "most innovative companies in the world" by Forbes magazine. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004, he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos attended the Bronx High School of Science and received his MD and PhD from Columbia University.


Close

Corporate Leaders

Maya Bermingham: Senior Vice President, Public Policy & Government Affairs

Maya Bermingham

Senior Vice President, Public Policy and Government Affairs

Maya Bermingham, JD, joined Regeneron in 2015 and serves as Senior Vice President, Public Policy and Government Affairs. Ms. Bermingham and her Washington, DC-based team play a critical role in helping Regeneron shape and maintain its industry-leading reputation among governmental stakeholders. In 2020, Ms. Bermingham stepped forward to also serve as the company’s interim head of Diversity, Equity and Inclusion (DE&I). Prior to joining Regeneron, Ms. Bermingham held roles of increasing responsibility at PhRMA over a 12 year tenure, following earlier positions at legal firms, and work for Senator Moynihan and the Senate Finance Committee. She received her BA from Harvard University and her JD from New York University.

Maya Bermingham

Senior Vice President, Public Policy and Government Affairs

Maya Bermingham, JD, joined Regeneron in 2015 and serves as Senior Vice President, Public Policy and Government Affairs. Ms. Bermingham and her Washington, DC-based team play a critical role in helping Regeneron shape and maintain its industry-leading reputation among governmental stakeholders. In 2020, Ms. Bermingham stepped forward to also serve as the company’s interim head of Diversity, Equity and Inclusion (DE&I). Prior to joining Regeneron, Ms. Bermingham held roles of increasing responsibility at PhRMA over a 12 year tenure, following earlier positions at legal firms, and work for Senator Moynihan and the Senate Finance Committee. She received her BA from Harvard University and her JD from New York University.

Close

Chris Fenimore: Senior Vice President, Head of Accounting and Controller

Chris Fenimore

Senior Vice President, Head of Accounting and Controller

Chris Fenimore joined Regeneron in 2003 and, as the current Head of Accounting and Controller, has global responsibility for SEC reporting, accounting and accounting operations, and internal control over financial reporting, administration of financial systems, accounts payable and payroll. Prior to his current role, he served as Regeneron’s Vice President of Financial Planning, and prior to joining Regeneron, he was Vice President of Finance at Mojave Therapeutics, Inc. He has prior experience in healthcare industry-focused venture capital and investment banking roles, as well as serving as an audit senior at KPMG. Mr. Fenimore holds an MA in Biotechnology from Columbia University, an MBA in Professional Accounting from Rutgers Business School and a BA in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York. 

Chris Fenimore

Senior Vice President, Head of Accounting and Controller

Chris Fenimore joined Regeneron in 2003 and, as the current Head of Accounting and Controller, has global responsibility for SEC reporting, accounting and accounting operations, and internal control over financial reporting, administration of financial systems, accounts payable and payroll. Prior to his current role, he served as Regeneron’s Vice President of Financial Planning, and prior to joining Regeneron, he was Vice President of Finance at Mojave Therapeutics, Inc. He has prior experience in healthcare industry-focused venture capital and investment banking roles, as well as serving as an audit senior at KPMG. Mr. Fenimore holds an MA in Biotechnology from Columbia University, an MBA in Professional Accounting from Rutgers Business School and a BA in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York. 

Close

Beth F. Holly: Senior Vice President, Associate General Counsel and Chief Compliance Officer

Beth F. Holly

Senior Vice President, Associate General Counsel and Chief Compliance Officer

Beth F. Holly joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Prior to joining Regeneron, Ms. Holly spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. In the early days of her legal career, Ms. Holly was a litigation associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Ms. Holly received a BS from Cornell University and a JD degree from Fordham Law School.

Beth F. Holly

Senior Vice President, Associate General Counsel and Chief Compliance Officer

Beth F. Holly joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Prior to joining Regeneron, Ms. Holly spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. In the early days of her legal career, Ms. Holly was a litigation associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Ms. Holly received a BS from Cornell University and a JD degree from Fordham Law School.

Close

Nouhad Husseini: Senior Vice President, Business Development

Nouhad Husseini

Senior Vice President, Business Development

Nouhad Husseini joined Regeneron in 2011 and is head of Business Development, overseeing the company’s efforts to execute new strategic collaborations and licensing agreements. He has nearly 20 years of experience in the biopharmaceutical industry, where he has held a variety of strategic, business development and finance roles, including in Genentech’s Business Development and Corporate Finance departments and in investment banking and equity research at Morgan Stanley and Robertson Stephens. Mr. Husseini received his undergraduate degree in Molecular Biology from Princeton University and MBA from the Wharton School at University of Pennsylvania.

Nouhad Husseini

Senior Vice President, Business Development

Nouhad Husseini joined Regeneron in 2011 and is head of Business Development, overseeing the company’s efforts to execute new strategic collaborations and licensing agreements. He has nearly 20 years of experience in the biopharmaceutical industry, where he has held a variety of strategic, business development and finance roles, including in Genentech’s Business Development and Corporate Finance departments and in investment banking and equity research at Morgan Stanley and Robertson Stephens. Mr. Husseini received his undergraduate degree in Molecular Biology from Princeton University and MBA from the Wharton School at University of Pennsylvania.

Close

Robert E. Landry: Executive Vice President, Finance and Chief Financial Officer

Robert E. Landry

Executive Vice President, Finance and Chief Financial Officer

Robert E. Landry joined Regeneron in 2013 and serves as Executive Vice President, Finance and Chief Financial Officer. Prior to joining Regeneron, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Mr. Landry also held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.

Robert E. Landry

Executive Vice President, Finance and Chief Financial Officer

Robert E. Landry joined Regeneron in 2013 and serves as Executive Vice President, Finance and Chief Financial Officer. Prior to joining Regeneron, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Mr. Landry also held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.

Close

Joseph J. LaRosa: Executive Vice President, General Counsel and Secretary

Joseph J. LaRosa

Executive Vice President, General Counsel and Secretary

Joseph J. LaRosa joined Regeneron in 2011 and is currently Executive Vice President, General Counsel and Secretary. Prior to joining Regeneron, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. He also previously served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc., and held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served as Vice President, Legal Affairs, and a member of the Operations Management Team. Mr. LaRosa received his JD degree from New York University.

Joseph J. LaRosa

Executive Vice President, General Counsel and Secretary

Joseph J. LaRosa joined Regeneron in 2011 and is currently Executive Vice President, General Counsel and Secretary. Prior to joining Regeneron, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. He also previously served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc., and held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served as Vice President, Legal Affairs, and a member of the Operations Management Team. Mr. LaRosa received his JD degree from New York University.

Close

Marion McCourt: Senior Vice President, Commercial

Marion McCourt

Executive Vice President, Commercial

Marion McCourt joined Regeneron in 2018 and serves as Executive Vice President and Head of the Commercial organization. Prior to joining Regeneron, Ms. McCourt worked at Axovant, a clinical-stage biopharmaceutical company, where she was President and Chief Operating Officer. She served as Chief Operating Officer of Medivation until it was acquired by Pfizer Inc. in 2016, and before that held commercial leadership roles at Amgen, including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company’s bone health and primary care business unit. Ms. McCourt began her career and spent 12 year at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She received her BS from Lafayette College.

Marion McCourt

Executive Vice President, Commercial

Marion McCourt joined Regeneron in 2018 and serves as Executive Vice President and Head of the Commercial organization. Prior to joining Regeneron, Ms. McCourt worked at Axovant, a clinical-stage biopharmaceutical company, where she was President and Chief Operating Officer. She served as Chief Operating Officer of Medivation until it was acquired by Pfizer Inc. in 2016, and before that held commercial leadership roles at Amgen, including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company’s bone health and primary care business unit. Ms. McCourt began her career and spent 12 year at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She received her BS from Lafayette College.

Close

Bob McCowan: Senior Vice President, IT and Chief Information Officer

Bob McCowan

Senior Vice President, IT and Chief Information Officer

Bob McCowan is Senior Vice President and Chief Information Officer at Regeneron. With over 30 years global experience, Mr. McCowan leads the company’s IT organization and is responsible for global IT strategy supporting Research, Commercial, Cyber Security and Enterprise operations. He has driven an enhanced company focus on big data, innovation and strategic IT investments that support Regeneron’s mission. Mr. McCowan previously worked at international organizations including Amgen, Artemis International, Computer Science Corporation and Lockheed. He earned his MBA with the UK Open University and holds a degree in Electrical Engineering.

Bob McCowan

Senior Vice President, IT and Chief Information Officer

Bob McCowan is Senior Vice President and Chief Information Officer at Regeneron. With over 30 years global experience, Mr. McCowan leads the company’s IT organization and is responsible for global IT strategy supporting Research, Commercial, Cyber Security and Enterprise operations. He has driven an enhanced company focus on big data, innovation and strategic IT investments that support Regeneron’s mission. Mr. McCowan previously worked at international organizations including Amgen, Artemis International, Computer Science Corporation and Lockheed. He earned his MBA with the UK Open University and holds a degree in Electrical Engineering.

Close

Gonzalo Merino, PhD: Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel

Gonzalo Merino, PhD

Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel

Gonzalo Merino, PhD, JD, joined Regeneron in 2013 and now serves as Senior Vice President and Chief Intellectual Property Counsel. He is responsible for protecting Regeneron’s Intellectual Property, including by developing and implementing a comprehensive global IP strategy. Prior to joining Regeneron, Dr. Merino was an Associate General Counsel at Columbia University and a patent attorney at Bryan Cave LLP in New York City. He obtained his JD from Columbia University Law School, where he was a Harlan Fisk Stone Scholar, and his PhD from the Integrated Program in Cellular, Molecular and Biophysical Studies at the Columbia University Graduate School of Arts and Sciences, where he received the Richard C. Parker Award for Outstanding and Innovative Research and a Minority Pre-doctoral Fellowship Award.

Gonzalo Merino, PhD

Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel

Gonzalo Merino, PhD, JD, joined Regeneron in 2013 and now serves as Senior Vice President and Chief Intellectual Property Counsel. He is responsible for protecting Regeneron’s Intellectual Property, including by developing and implementing a comprehensive global IP strategy. Prior to joining Regeneron, Dr. Merino was an Associate General Counsel at Columbia University and a patent attorney at Bryan Cave LLP in New York City. He obtained his JD from Columbia University Law School, where he was a Harlan Fisk Stone Scholar, and his PhD from the Integrated Program in Cellular, Molecular and Biophysical Studies at the Columbia University Graduate School of Arts and Sciences, where he received the Richard C. Parker Award for Outstanding and Innovative Research and a Minority Pre-doctoral Fellowship Award.

Close

Hala Mirza: Senior Vice President, Corporate Communications & Citizenship

Hala Mirza

Senior Vice President, Corporate Communications and Citizenship

Hala Mirza joined Regeneron in 2014 and serves as Senior Vice President, Corporate Communications and Citizenship, leading corporate reputation, internal and external communications, patient advocacy and corporate citizenship. Before joining Regeneron, she was Vice President, Corporate Affairs for R&D and Strategy at Pfizer Inc. Prior to joining Pfizer, Ms. Mirza was Managing Director at W2O Group, a leading healthcare communications agency. She also previously served as Public Relations Officer at the American Red Cross Biomedical Services. Ms. Mirza received her BA from The George Washington University.

Hala Mirza

Senior Vice President, Corporate Communications and Citizenship

Hala Mirza joined Regeneron in 2014 and serves as Senior Vice President, Corporate Communications and Citizenship, leading corporate reputation, internal and external communications, patient advocacy and corporate citizenship. Before joining Regeneron, she was Vice President, Corporate Affairs for R&D and Strategy at Pfizer Inc. Prior to joining Pfizer, Ms. Mirza was Managing Director at W2O Group, a leading healthcare communications agency. She also previously served as Public Relations Officer at the American Red Cross Biomedical Services. Ms. Mirza received her BA from The George Washington University.

Close

Sally A. Paull: Senior Vice President, Human Resources

Sally A. Paull

Senior Vice President, Human Resources

Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. She was previously Executive Vice President, Chief Human Resources Officer at Inova Health System. Prior to Inova, Ms. Paull was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. She received her BS from the United States Air Force Academy and her Master’s in International Relations from the University of Delaware.

Sally A. Paull

Senior Vice President, Human Resources

Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. She was previously Executive Vice President, Chief Human Resources Officer at Inova Health System. Prior to Inova, Ms. Paull was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. She received her BS from the United States Air Force Academy and her Master’s in International Relations from the University of Delaware.

Close

Smita Pillai: Chief Diversity, Equity & Inclusion Officer

Smita Pillai

Chief Diversity, Equity and Inclusion Officer

Smita Pillai joined Regeneron as our first Chief Diversity, Equity & Inclusion (DE&I) Officer in 2021. Ms. Pillai has an accomplished global DE&I career spanning Life Sciences, Technology, Financial Services and Media sectors. Most recently she was VP, Global Head of DE&I at Zendesk. Prior to that she was Chief Diversity Officer for Dow Jones, including its flagship brand The Wall Street Journal. Before that, she has led global marketing research, corporate strategy and DE&I efforts at Fortune 50 companies such as Prudential Financial, Johnson & Johnson and ACNielsen. A certified DE&I professional, Ms. Pillai received her BBA from KS School of Management and MBA from Symbiosis International Business School, India.

Smita Pillai

Chief Diversity, Equity and Inclusion Officer

Smita Pillai joined Regeneron as our first Chief Diversity, Equity & Inclusion (DE&I) Officer in 2021. Ms. Pillai has an accomplished global DE&I career spanning Life Sciences, Technology, Financial Services and Media sectors. Most recently she was VP, Global Head of DE&I at Zendesk. Prior to that she was Chief Diversity Officer for Dow Jones, including its flagship brand The Wall Street Journal. Before that, she has led global marketing research, corporate strategy and DE&I efforts at Fortune 50 companies such as Prudential Financial, Johnson & Johnson and ACNielsen. A certified DE&I professional, Ms. Pillai received her BBA from KS School of Management and MBA from Symbiosis International Business School, India.

Close

Kerry Reinertsen, PhD: Senior Vice President, Strategic Alliances

Kerry Reinertsen, PhD

Senior Vice President, Strategic Alliances

Kerry Reinertsen, PhD, joined Regeneron in 2011 and serves as Senior Vice President of Strategic Alliances. Prior to joining Regeneron, she was Chief Business Officer of Constellation Pharmaceuticals. Before this, Dr. Reinertsen served as the Vice President of Corporate Development at Vertex Pharmaceuticals. Dr. Reinertsen started her biotech career at Millennium Pharmaceuticals (now Takeda Oncology) where she held positions of increasing responsibility in business development. Dr. Reinertsen received her PhD in Biological Chemistry and Molecular Pharmacology from Harvard University and her ScB in Molecular Biology and AB in Economics from Brown University.

Kerry Reinertsen, PhD

Senior Vice President, Strategic Alliances

Kerry Reinertsen, PhD, joined Regeneron in 2011 and serves as Senior Vice President of Strategic Alliances. Prior to joining Regeneron, she was Chief Business Officer of Constellation Pharmaceuticals. Before this, Dr. Reinertsen served as the Vice President of Corporate Development at Vertex Pharmaceuticals. Dr. Reinertsen started her biotech career at Millennium Pharmaceuticals (now Takeda Oncology) where she held positions of increasing responsibility in business development. Dr. Reinertsen received her PhD in Biological Chemistry and Molecular Pharmacology from Harvard University and her ScB in Molecular Biology and AB in Economics from Brown University.

Close

Deborah Tegan: Senior Vice President, Strategic Sourcing and Procurement

Deborah Tegan

Senior Vice President, Strategic Sourcing and Procurement

Deborah Tegan joined Regeneron in 2006 and serves as Senior Vice President, Strategic Sourcing and Procurement. Prior to joining Regeneron, Ms. Tegan worked at Ciba Specialty Chemicals and then as Senior Director/Head of Procurement at Purdue Pharma L.P., where she held roles of increasing responsibility. Ms. Tegan received her BS and MBA from Iona College.

Deborah Tegan

Senior Vice President, Strategic Sourcing and Procurement

Deborah Tegan joined Regeneron in 2006 and serves as Senior Vice President, Strategic Sourcing and Procurement. Prior to joining Regeneron, Ms. Tegan worked at Ciba Specialty Chemicals and then as Senior Director/Head of Procurement at Purdue Pharma L.P., where she held roles of increasing responsibility. Ms. Tegan received her BS and MBA from Iona College.

Close

Research and Development Leaders

Hanne Bak, PhD: Senior Vice President, Preclinical Manufacturing & Process Development

Hanne Bak, PhD

Senior Vice President, Preclinical Manufacturing and Process Development

Hanne Bak, PhD, joined Regeneron in 2004 and serves as Senior Vice President, Preclinical Manufacturing and Process Development (PMPD). She started her career at Regeneron as a research engineer working in the Purification Development group within PMPD and has subsequently held roles of increasing responsibility. Dr. Bak received her BS, MS and PhD in Chemical Engineering from Danmarks Tekniske Universitet (Technical University of Denmark).

Hanne Bak, PhD

Senior Vice President, Preclinical Manufacturing and Process Development

Hanne Bak, PhD, joined Regeneron in 2004 and serves as Senior Vice President, Preclinical Manufacturing and Process Development (PMPD). She started her career at Regeneron as a research engineer working in the Purification Development group within PMPD and has subsequently held roles of increasing responsibility. Dr. Bak received her BS, MS and PhD in Chemical Engineering from Danmarks Tekniske Universitet (Technical University of Denmark).

Close

Aris Baras, MD: Senior Vice President, Regeneron Genetics Center

Aris Baras, MD

Senior Vice President, Regeneron Genetics Center

Aris Baras, MD, joined Regeneron in 2011 and helped found the Regeneron Genetics Center (RGC), where he now serves as Senior Vice President. Previously, he held roles and responsibilities at Regeneron across R&D and business development. Prior to joining Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody-based therapeutics, cancer research and nanotechnology applications in drug development. Dr. Baras received his BS, MBA and MD from Duke University.

Aris Baras, MD

Senior Vice President, Regeneron Genetics Center

Aris Baras, MD, joined Regeneron in 2011 and helped found the Regeneron Genetics Center (RGC), where he now serves as Senior Vice President. Previously, he held roles and responsibilities at Regeneron across R&D and business development. Prior to joining Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody-based therapeutics, cancer research and nanotechnology applications in drug development. Dr. Baras received his BS, MBA and MD from Duke University.

Close

Ned Braunstein, MD: Senior Vice President, Regulatory Affairs, Global Patient Safety

Ned Braunstein, MD

Senior Vice President, Regulatory Affairs and Global Patient Safety

Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs and Global Patient Safety. Prior to joining Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine, and at Merck & Co., Inc. for nine years in positions of increasing responsibility in Clinical Research, Regulatory Affairs and Global Human Health. Dr. Braunstein received his BS in Medicine and his MD from Northwestern University.

Ned Braunstein, MD

Senior Vice President, Regulatory Affairs and Global Patient Safety

Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs and Global Patient Safety. Prior to joining Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine, and at Merck & Co., Inc. for nine years in positions of increasing responsibility in Clinical Research, Regulatory Affairs and Global Human Health. Dr. Braunstein received his BS in Medicine and his MD from Northwestern University.

Close

Gregory Geba, MD, PhD: Senior Vice President, Global Development Scientific Council

Gregory Geba, MD, PhD

Senior Vice President, Global Development Scientific Council

Gregory Geba, MD, PhD, joined Regeneron in 2013 and serves as Senior Vice President of the Global Development Scientific Council, a group that provides senior scientific input to Regeneron’s therapeutic portfolio of programs. He is a physician-scientist with decades of experience in design, execution and analysis of clinical trials. Previously, Dr. Geba worked at Sanofi, AstraZeneca, Novartis, Merck and Yale University as an Assistant Professor of Medicine. He received his BA in Biology from Brown University, MD from the University of Navarra, completed a Fellowship in Immunology/Pulmonary and Critical Care at Yale University, received an MPH in Epidemiology from The Johns Hopkins University, and his PhD in Molecular Toxicology from Columbia University.

Gregory Geba, MD, PhD

Senior Vice President, Global Development Scientific Council

Gregory Geba, MD, PhD, joined Regeneron in 2013 and serves as Senior Vice President of the Global Development Scientific Council, a group that provides senior scientific input to Regeneron’s therapeutic portfolio of programs. He is a physician-scientist with decades of experience in design, execution and analysis of clinical trials. Previously, Dr. Geba worked at Sanofi, AstraZeneca, Novartis, Merck and Yale University as an Assistant Professor of Medicine. He received his BA in Biology from Brown University, MD from the University of Navarra, completed a Fellowship in Immunology/Pulmonary and Critical Care at Yale University, received an MPH in Epidemiology from The Johns Hopkins University, and his PhD in Molecular Toxicology from Columbia University.

Close

Gary Herman, MD: Senior Vice President, Early Clinical Development & Experimental Sciences

Gary Herman, MD

Senior Vice President, Early Clinical Development and Experimental Sciences

Gary Herman, MD, joined Regeneron in 2015 and leads the Early Clinical Development and Experimental Sciences (ECDES) function. Previously, he served in roles of increasing responsibility at Merck, most recently as the Vice President and Head, Early Stage Development. From 2008 to 2015, Dr. Herman was one of only three pharmaceutical industry members on the Executive Committee of the Biomarkers Consortium, a program within the Foundation for the National Institutes of Health. Prior to that, Dr. Herman completed his residency and postdoctoral training at University of California, San Francisco and was an Assistant Professor there before joining industry. He received his BS in Biochemistry and Cell Biology from the University of California, San Diego, and his MD from Harvard Medical School.

Gary Herman, MD

Senior Vice President, Early Clinical Development and Experimental Sciences

Gary Herman, MD, joined Regeneron in 2015 and leads the Early Clinical Development and Experimental Sciences (ECDES) function. Previously, he served in roles of increasing responsibility at Merck, most recently as the Vice President and Head, Early Stage Development. From 2008 to 2015, Dr. Herman was one of only three pharmaceutical industry members on the Executive Committee of the Biomarkers Consortium, a program within the Foundation for the National Institutes of Health. Prior to that, Dr. Herman completed his residency and postdoctoral training at University of California, San Francisco and was an Assistant Professor there before joining industry. He received his BS in Biochemistry and Cell Biology from the University of California, San Diego, and his MD from Harvard Medical School.

Close

Boaz Hirshberg

Boaz Hirshberg, MD, MBA

Senior Vice President, Clinical Sciences General Medicine 

Boaz Hirshberg, MD, MBA, joined Regeneron in 2021 and serves as Senior Vice President, Clinical Sciences General Medicine, leading strategic program direction and late stage clinical development for a broad range of therapeutic areas including ophthalmology, cardiovascular and metabolic, pain and neurology, and infectious and rare diseases. Before joining Regeneron, Dr. Hirshberg was Executive Vice President, Chief Medical Officer and Head of Global Development at BOL Pharma, a biotech developing medical cannabis therapeutics, where he directed preclinical and clinical development, regulatory, pharmacovigilance and medical affairs. Prior to BOL, he spent 12 years at AstraZeneca/MedImmune in roles of increasing responsibility, ultimately building and overseeing the Cardiovascular Renal and Metabolism clinical therapeutic area at MedImmune. Dr. Hirshberg completed his undergraduate and Medical Degrees at the Hebrew University and is Board Certified in internal medicine, following his residency at the Hadassah Medical center in Jerusalem. He received his MBA in Health Care Administration from Wilmington University.

Boaz Hirshberg, MD, MBA

Senior Vice President, Clinical Sciences General Medicine 

Boaz Hirshberg, MD, MBA, joined Regeneron in 2021 and serves as Senior Vice President, Clinical Sciences General Medicine, leading strategic program direction and late stage clinical development for a broad range of therapeutic areas including ophthalmology, cardiovascular and metabolic, pain and neurology, and infectious and rare diseases. Before joining Regeneron, Dr. Hirshberg was Executive Vice President, Chief Medical Officer and Head of Global Development at BOL Pharma, a biotech developing medical cannabis therapeutics, where he directed preclinical and clinical development, regulatory, pharmacovigilance and medical affairs. Prior to BOL, he spent 12 years at AstraZeneca/MedImmune in roles of increasing responsibility, ultimately building and overseeing the Cardiovascular Renal and Metabolism clinical therapeutic area at MedImmune. Dr. Hirshberg completed his undergraduate and Medical Degrees at the Hebrew University and is Board Certified in internal medicine, following his residency at the Hadassah Medical center in Jerusalem. He received his MBA in Health Care Administration from Wilmington University.

Close

Bari Kowal: Senior Vice President, Development Operations and Portfolio Planning

Bari Kowal

Senior Vice President, Development Operations and Portfolio Management

Bari Kowal joined Regeneron in 2015 and became Head of Global Clinical Operations in 2017. She currently serves as Senior Vice President, Development Operations and Portfolio Management and is responsible for clinical trial strategy and execution, along with overseeing our development shared services functions. She was previously at Pfizer where she held the positions of Vice President, Business Operations and Analytics, and, prior to that, Vice President, Strategic Alliance and Development Operations Lead. Ms. Kowal also served as Vice President, Clinical Operations, on the clinical research organization side of the industry at a number of biotech organizations in a variety of clinical research roles early in her career. She holds a BS in Biology from the State University of New York at Binghamton and an MS in Neuroscience from New York University.

Bari Kowal

Senior Vice President, Development Operations and Portfolio Management

Bari Kowal joined Regeneron in 2015 and became Head of Global Clinical Operations in 2017. She currently serves as Senior Vice President, Development Operations and Portfolio Management and is responsible for clinical trial strategy and execution, along with overseeing our development shared services functions. She was previously at Pfizer where she held the positions of Vice President, Business Operations and Analytics, and, prior to that, Vice President, Strategic Alliance and Development Operations Lead. Ms. Kowal also served as Vice President, Clinical Operations, on the clinical research organization side of the industry at a number of biotech organizations in a variety of clinical research roles early in her career. She holds a BS in Biology from the State University of New York at Binghamton and an MS in Neuroscience from New York University.

Close

Johnathan Lancaster, MD, PhD: Senior Vice President, Global Medical Affairs

Johnathan Lancaster, MD, PhD

Senior Vice President, Global Medical Affairs

Johnathan M. Lancaster, MD, PhD, joined Regeneron in 2019 as a Vice President and now serves as SVP and Head of Global Medical Affairs. Prior to joining Regeneron, Dr. Lancaster served as Chief Medical Officer at Myriad Genetics, Inc., following more than a decade in academics at Moffitt Comprehensive Cancer Center in Tampa as a gynecologic oncologist, molecular genetics researcher, and ultimately President of the Moffitt Medical Group Corporation. Dr. Lancaster received his BSc in Pharmacology and his MD and PhD from the University of Wales in the UK. He received post graduate clinical training in OBGYN and Gynecologic Oncology at the University of Cambridge and Duke University Medical Center.

Johnathan Lancaster, MD, PhD

Senior Vice President, Global Medical Affairs

Johnathan M. Lancaster, MD, PhD, joined Regeneron in 2019 as a Vice President and now serves as SVP and Head of Global Medical Affairs. Prior to joining Regeneron, Dr. Lancaster served as Chief Medical Officer at Myriad Genetics, Inc., following more than a decade in academics at Moffitt Comprehensive Cancer Center in Tampa as a gynecologic oncologist, molecular genetics researcher, and ultimately President of the Moffitt Medical Group Corporation. Dr. Lancaster received his BSc in Pharmacology and his MD and PhD from the University of Wales in the UK. He received post graduate clinical training in OBGYN and Gynecologic Oncology at the University of Cambridge and Duke University Medical Center.

Close

John Lin, MD, PhD: Senior Vice President, Immuno-Oncology & Head of Bispecifics

John Lin, MD, PhD

Senior Vice President, Immuno-Oncology and Head of Bispecifics

John Lin, MD, PhD, joined Regeneron in 2016 and oversees the preclinical bispecific antibody research work in Research and Development across all disease areas. Previously, he worked at Pfizer for 10 years focusing on research and early development of biologics, and before that he worked at Rinat Neuroscience Corporation after completing his postdoctoral fellowship at Genentech. Dr. Lin received his MD from National Taiwan University and his PhD from Harvard University.

John Lin, MD, PhD

Senior Vice President, Immuno-Oncology and Head of Bispecifics

John Lin, MD, PhD, joined Regeneron in 2016 and oversees the preclinical bispecific antibody research work in Research and Development across all disease areas. Previously, he worked at Pfizer for 10 years focusing on research and early development of biologics, and before that he worked at Rinat Neuroscience Corporation after completing his postdoctoral fellowship at Genentech. Dr. Lin received his MD from National Taiwan University and his PhD from Harvard University.

Close

Israel Lowy, MD, PhD: Senior Vice President, Translational and Clinical Sciences, Oncology

Israel Lowy, MD, PhD

Senior Vice President, Translational and Clinical Sciences, Oncology

Israel Lowy, MD, PhD, joined Regeneron in 2010 as Vice President, and now serves as Senior Vice President, Translational and Clinical Sciences, Oncology. He is a primary architect of Regeneron’s cancer immunotherapy program. Prior to joining Regeneron, Dr. Lowy was at Medarex for eight years. Before that, he was Assistant Professor of Medicine and Microbiology at Mount Sinai School of Medicine. Dr. Lowy is a licensed physician and has been board certified in internal medicine and infectious diseases. He received his AB in Biochemical Sciences from Princeton University and his MD-PhD in Biochemistry and Molecular Biophysics from Columbia University.

Israel Lowy, MD, PhD

Senior Vice President, Translational and Clinical Sciences, Oncology

Israel Lowy, MD, PhD, joined Regeneron in 2010 as Vice President, and now serves as Senior Vice President, Translational and Clinical Sciences, Oncology. He is a primary architect of Regeneron’s cancer immunotherapy program. Prior to joining Regeneron, Dr. Lowy was at Medarex for eight years. Before that, he was Assistant Professor of Medicine and Microbiology at Mount Sinai School of Medicine. Dr. Lowy is a licensed physician and has been board certified in internal medicine and infectious diseases. He received his AB in Biochemical Sciences from Princeton University and his MD-PhD in Biochemistry and Molecular Biophysics from Columbia University.

Close

Andrew (Drew) Murphy, PhD: Executive Vice President, Research

Andrew Murphy, PhD

Executive Vice President, Research

Andrew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics and is now Executive Vice President of Research. In his time at the company, he has led the Gene Discovery and Bioinformatics and Target Discovery groups. Dr. Murphy is a co-inventor of several of Regeneron's key technologies, <em>VelociGene<sup>®</sup></em> and <em>VelocImmune<sup>®</sup></em>, and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

Andrew Murphy, PhD

Executive Vice President, Research

Andrew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics and is now Executive Vice President of Research. In his time at the company, he has led the Gene Discovery and Bioinformatics and Target Discovery groups. Dr. Murphy is a co-inventor of several of Regeneron's key technologies, VelociGene® and VelocImmune®, and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

Close

William Olson, PhD: Senior Vice President, Therapeutic Proteins

William Olson, PhD

Senior Vice President, Therapeutic Proteins

William Olson, PhD, joined Regeneron in 2013 as Vice President and now serves as Senior Vice President of Therapeutic Proteins, where he is responsible for antibody generation, a key component of drug discovery, through innovative technologies. Before joining Regeneron, he was at Progenics Pharmaceuticals for 19 years. Previously, Dr. Olson was a scientist at MicroGeneSys and Johnson & Johnson’s RW Johnson Pharmaceutical Research Institute. Dr. Olson received his BS in Chemical Engineering at the University of North Dakota, and his PhD in Biochemical Engineering from Massachusetts Institute of Technology.

William Olson, PhD

Senior Vice President, Therapeutic Proteins

William Olson, PhD, joined Regeneron in 2013 as Vice President and now serves as Senior Vice President of Therapeutic Proteins, where he is responsible for antibody generation, a key component of drug discovery, through innovative technologies. Before joining Regeneron, he was at Progenics Pharmaceuticals for 19 years. Previously, Dr. Olson was a scientist at MicroGeneSys and Johnson & Johnson’s RW Johnson Pharmaceutical Research Institute. Dr. Olson received his BS in Chemical Engineering at the University of North Dakota, and his PhD in Biochemical Engineering from Massachusetts Institute of Technology.

Close

L. Andres Sirulnik, MD, PhD: Senior Vice President, Translational & Clinical Sciences, Hematology

L. Andres Sirulnik, MD, PhD

Senior Vice President, Translational and Clinical Sciences, Hematology

L. Andres Sirulnik, MD, PhD joined Regeneron in 2020 and serves as Senior Vice President, Translational & Clinical Sciences, Hematology, leading strategic program direction and clinical sciences work for our early- and late-stage oncologic hematology and late-stage non-oncology hematology portfolios. Before joining Regeneron, Dr. Sirulnik was Chief Medical Officer at Merus N.V., a clinical-stage immuno-oncology company. Prior to Merus N.V., he spent a decade at Novartis in various roles of increasing responsibility, ultimately overseeing the clinical strategy for their immuno-oncology portfolio. Dr. Sirulnik is a licensed physician, formerly practicing at Dana-Farber Cancer Institute and Brigham and Women’s Hospital and was a fellow in hematology/oncology at Mount Sinai Health System. He completed his medical residency at North Shore Long Island Jewish (LIJ) Health System and conducted post doctorate work at Columbia University. He received his PhD in Medicine and Molecular Biology from King’s College, University of Cambridge and his MD from the University of Buenos Aires.

L. Andres Sirulnik, MD, PhD

Senior Vice President, Translational and Clinical Sciences, Hematology

L. Andres Sirulnik, MD, PhD joined Regeneron in 2020 and serves as Senior Vice President, Translational & Clinical Sciences, Hematology, leading strategic program direction and clinical sciences work for our early- and late-stage oncologic hematology and late-stage non-oncology hematology portfolios. Before joining Regeneron, Dr. Sirulnik was Chief Medical Officer at Merus N.V., a clinical-stage immuno-oncology company. Prior to Merus N.V., he spent a decade at Novartis in various roles of increasing responsibility, ultimately overseeing the clinical strategy for their immuno-oncology portfolio. Dr. Sirulnik is a licensed physician, formerly practicing at Dana-Farber Cancer Institute and Brigham and Women’s Hospital and was a fellow in hematology/oncology at Mount Sinai Health System. He completed his medical residency at North Shore Long Island Jewish (LIJ) Health System and conducted post doctorate work at Columbia University. He received his PhD in Medicine and Molecular Biology from King’s College, University of Cambridge and his MD from the University of Buenos Aires.

Close

Randy Soltys, PhD: Senior Vice President, Drug Safety and Pharmacometrics

Randy Soltys, PhD

Senior Vice President, Drug Safety and Pharmacometrics

Randy Soltys, PhD, joined Regeneron in 2011 and now serves as Senior Vice President, Drug Safety and Pharmacometrics, where he is responsible for the Toxicology, Pathology, Preclinical PK/PD and Clinical and Quantitative Pharmacology organizations. Prior to joining Regeneron, he held senior leadership positions in Drug Safety Assessment at Genentech and Bristol-Myers Squibb. Dr. Soltys received his BS in Microbiology from Rutgers University and his PhD in Pharmacology/Toxicology jointly from Rutgers and the University of Medicine and Dentistry of New Jersey, and has been board-certified in Toxicology.

Randy Soltys, PhD

Senior Vice President, Drug Safety and Pharmacometrics

Randy Soltys, PhD, joined Regeneron in 2011 and now serves as Senior Vice President, Drug Safety and Pharmacometrics, where he is responsible for the Toxicology, Pathology, Preclinical PK/PD and Clinical and Quantitative Pharmacology organizations. Prior to joining Regeneron, he held senior leadership positions in Drug Safety Assessment at Genentech and Bristol-Myers Squibb. Dr. Soltys received his BS in Microbiology from Rutgers University and his PhD in Pharmacology/Toxicology jointly from Rutgers and the University of Medicine and Dentistry of New Jersey, and has been board-certified in Toxicology.

Close

Neil Stahl, PhD: Executive Vice President, Research & Development

Neil Stahl, PhD

Executive Vice President, Research and Development

Neil Stahl, PhD, joined Regeneron in 1991 and has served as Executive Vice President, Research and Development since January 2015. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research working on cytokine receptor signaling, and he spearheaded the invention and development of Regeneron’s Trap Technology. Prior to joining Regeneron, Dr. Stahl received his BS degree from Duke University and his PhD in Biochemistry from Brandeis University, then conducted post-doctoral research and was a faculty member at the University of California, San Francisco.

Neil Stahl, PhD

Executive Vice President, Research and Development

Neil Stahl, PhD, joined Regeneron in 1991 and has served as Executive Vice President, Research and Development since January 2015. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research working on cytokine receptor signaling, and he spearheaded the invention and development of Regeneron’s Trap Technology. Prior to joining Regeneron, Dr. Stahl received his BS degree from Duke University and his PhD in Biochemistry from Brandeis University, then conducted post-doctoral research and was a faculty member at the University of California, San Francisco.


Close

Gavin Thurston, PhD: Senior Vice President, Oncology Research

Gavin Thurston, PhD

Senior Vice President, Oncology Research

Gavin Thurston, PhD, joined Regeneron in 2001 initially to study the interaction of the VEGF signaling pathway with other angiogenic pathways and to target these pathways for the treatment of cancer. He now serves as Senior Vice President of Oncology Research, and leads the company’s cancer research efforts, including targeting tumor cells with an expanding library of bispecific and costimulatory bispecific antibodies. Prior to joining Regeneron, he was at University of California, San Francisco studying tumor vascular biology. Dr. Thurston received his BS in Physics at Yale University and his PhD in Biophysics from the University of British Columbia.

Gavin Thurston, PhD

Senior Vice President, Oncology Research

Gavin Thurston, PhD, joined Regeneron in 2001 initially to study the interaction of the VEGF signaling pathway with other angiogenic pathways and to target these pathways for the treatment of cancer. He now serves as Senior Vice President of Oncology Research, and leads the company’s cancer research efforts, including targeting tumor cells with an expanding library of bispecific and costimulatory bispecific antibodies. Prior to joining Regeneron, he was at University of California, San Francisco studying tumor vascular biology. Dr. Thurston received his BS in Physics at Yale University and his PhD in Biophysics from the University of British Columbia.

Close

David Weinreich, MD, MBA: Senior Vice President, Global Clinical Development

David Weinreich, MD, MBA

Executive Vice President, Global Clinical Development

David Weinreich, MD, joined Regeneron in 2016 and serves as Executive Vice President, Global Clinical Development. Prior to this role, he was Senior Vice President, Late Stage Clinical Development and Medical Affairs. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Before that, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his BS in computer engineering from Columbia University, his MBA from the McDonough School of Business at Georgetown University and his MD from Boston University School of Medicine.

David Weinreich, MD, MBA

Executive Vice President, Global Clinical Development

David Weinreich, MD, joined Regeneron in 2016 and serves as Executive Vice President, Global Clinical Development. Prior to this role, he was Senior Vice President, Late Stage Clinical Development and Medical Affairs. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Before that, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his BS in computer engineering from Columbia University, his MBA from the McDonough School of Business at Georgetown University and his MD from Boston University School of Medicine.

Close

Brian Zambrowicz, PhD: Senior Vice President, Functional Genomics and Chief VelociGene® Operations

Brian Zambrowicz, PhD

Senior Vice President, Functional Genomics and Chief VelociGene® Operations

Brian Zambrowicz, PhD, joined Regeneron in 2015 and serves as Senior Vice President, Functional Genomics and Chief VelociGene® Operations. Prior to joining Regeneron, Dr. Zambrowicz held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as Executive Vice President and Chief Scientific Officer. Dr. Zambrowicz received his BS from the University of Wisconsin-Madison and his PhD from the University of Washington.

Brian Zambrowicz, PhD

Senior Vice President, Functional Genomics and Chief VelociGene® Operations

Brian Zambrowicz, PhD, joined Regeneron in 2015 and serves as Senior Vice President, Functional Genomics and Chief VelociGene® Operations. Prior to joining Regeneron, Dr. Zambrowicz held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as Executive Vice President and Chief Scientific Officer. Dr. Zambrowicz received his BS from the University of Wisconsin-Madison and his PhD from the University of Washington.

Close

Industrial Operations and
Product Supply Leaders

Gerald Carreau: Senior Vice President, Commercial Scale Manufacturing & Manufacturing Technology

Gerald Carreau

Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology

Gerald Carreau joined Regeneron in 2008 and serves as Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology. Prior to Regeneron, Mr. Carreau worked at Novartis (formerly Chiron Corporation). He earned his BS from Virginia Polytechnic Institute and State University.

Gerald Carreau

Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology

Gerald Carreau joined Regeneron in 2008 and serves as Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology. Prior to Regeneron, Mr. Carreau worked at Novartis (formerly Chiron Corporation). He earned his BS from Virginia Polytechnic Institute and State University.

Close

Scott Carver, PhD: Senior Vice President, Manufacturing and Process Sciences

Scott Carver, PhD

Senior Vice President, Manufacturing and Process Sciences

Scott Carver, PhD, joined Regeneron in 1998 and serves as Senior Vice President, Manufacturing and Process Sciences. He previously held roles in Process Development and Preclinical Manufacturing, Clinical Manufacturing and Manufacturing Sciences. Dr. Carver earned his BS in Chemical Engineering from the University of Nevada, Reno and his PhD in Chemical Engineering from Iowa State University.

Scott Carver, PhD

Senior Vice President, Manufacturing and Process Sciences

Scott Carver, PhD, joined Regeneron in 1998 and serves as Senior Vice President, Manufacturing and Process Sciences. He previously held roles in Process Development and Preclinical Manufacturing, Clinical Manufacturing and Manufacturing Sciences. Dr. Carver earned his BS in Chemical Engineering from the University of Nevada, Reno and his PhD in Chemical Engineering from Iowa State University.

Close

Patrice Gilooly: Senior Vice President, Quality Assurance & Operations

Patrice Gilooly

Senior Vice President, Quality Assurance and Operations

Patrice Gilooly joined Regeneron in 1998 and serves as Senior Vice President, Quality Assurance and Operations. Ms. Gilooly has held positions of increasing responsibility in Validation and Quality Assurance and Operations. Prior to joining Regeneron, she worked at Raytheon Engineers & Construction, Genzyme Corporation and Repligen Corporation. Ms. Gilooly earned a BS in Biology from the University of Massachusetts.

Patrice Gilooly

Senior Vice President, Quality Assurance and Operations

Patrice Gilooly joined Regeneron in 1998 and serves as Senior Vice President, Quality Assurance and Operations. Ms. Gilooly has held positions of increasing responsibility in Validation and Quality Assurance and Operations. Prior to joining Regeneron, she worked at Raytheon Engineers & Construction, Genzyme Corporation and Repligen Corporation. Ms. Gilooly earned a BS in Biology from the University of Massachusetts.

Close

Jenny McNay, PhD: Senior Vice President, CMC Regulatory Sciences and Industrial Affairs

Jenny McNay, PhD

Senior Vice President, CMC Regulatory Sciences and Industrial Affairs

Jennifer McNay, PhD, joined Regeneron in 2000 and serves as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) Regulatory Sciences and Industrial Affairs. She previously held roles at Regeneron in Preclinical Manufacturing and Process Development, Process Sciences and Combination Products. Prior to joining Regeneron, she worked at Procter and Gamble. Dr. McNay earned her BS in Chemical Engineering from the University of Delaware and her MS and PhD in Chemical Engineering from the University of Virginia.

Jenny McNay, PhD

Senior Vice President, CMC Regulatory Sciences and Industrial Affairs

Jennifer McNay, PhD, joined Regeneron in 2000 and serves as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) Regulatory Sciences and Industrial Affairs. She previously held roles at Regeneron in Preclinical Manufacturing and Process Development, Process Sciences and Combination Products. Prior to joining Regeneron, she worked at Procter and Gamble. Dr. McNay earned her BS in Chemical Engineering from the University of Delaware and her MS and PhD in Chemical Engineering from the University of Virginia.

Close

Niall O’Leary: Senior Vice President and Site Head, IOPS Raheen

Niall O’Leary

Senior Vice President and Site Head, IOPS Raheen

Niall O’Leary joined Regeneron in 2012 and serves as Senior Vice President and Site Head of IOPS Raheen. He has held leadership positions of increasing responsibility in Quality, Regulatory Affairs, Program Management and Manufacturing across biological, small molecule and medical device platforms. Prior to joining Regeneron, Mr. O’Leary has worked as an independent consultant and at Pulmatrix, Alkermes, Organogenesis and Merck Serono. Mr. O’Leary received his BS in Biotechnology from Dublin City University, Ireland and his MBA from the Williams College of Business at Xavier University in Cincinnati, Ohio.

Niall O’Leary

Senior Vice President and Site Head, IOPS Raheen

Niall O’Leary joined Regeneron in 2012 and serves as Senior Vice President and Site Head of IOPS Raheen. He has held leadership positions of increasing responsibility in Quality, Regulatory Affairs, Program Management and Manufacturing across biological, small molecule and medical device platforms. Prior to joining Regeneron, Mr. O’Leary has worked as an independent consultant and at Pulmatrix, Alkermes, Organogenesis and Merck Serono. Mr. O’Leary received his BS in Biotechnology from Dublin City University, Ireland and his MBA from the Williams College of Business at Xavier University in Cincinnati, Ohio.

Close

Gerald Underwood: Senior Vice President, Technical Operations

Gerald Underwood

Senior Vice President, Technical Operations

Gerald Underwood joined Regeneron in 1995 and serves as Senior Vice President, Technical Operations for the global Industrial Operations & Product Supply organization. He has held leadership roles in Quality, Validation, Regulatory, Internal Manufacturing and Engineering. Before joining Regeneron, Mr. Underwood worked at Fluor Daniel, the Jacobs Engineering Group and Day Laboratories. He holds a BS in Science from the University of California, Davis.

Gerald Underwood

Senior Vice President, Technical Operations

Gerald Underwood joined Regeneron in 1995 and serves as Senior Vice President, Technical Operations for the global Industrial Operations & Product Supply organization. He has held leadership roles in Quality, Validation, Regulatory, Internal Manufacturing and Engineering. Before joining Regeneron, Mr. Underwood worked at Fluor Daniel, the Jacobs Engineering Group and Day Laboratories. He holds a BS in Science from the University of California, Davis.

Close

Daniel Van Plew: Executive Vice President & General Manager, Industrial Operations & Product Supply

Daniel Van Plew

Executive Vice President and General Manager, Industrial Operations and Product Supply

Daniel Van Plew joined Regeneron in 2007 and has served as Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. From 2006 to 2007, he served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, he held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his MS in Chemistry from Penn State University and his MBA from Michigan State University.

Daniel Van Plew

Executive Vice President and General Manager, Industrial Operations and Product Supply

Daniel Van Plew joined Regeneron in 2007 and has served as Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. From 2006 to 2007, he served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, he held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his MS in Chemistry from Penn State University and his MBA from Michigan State University.


Close

Ron Wang, PhD: Senior Vice President, Quality Control

Ron Wang, PhD

Senior Vice President, Quality Control

Ron Wang, PhD, joined Regeneron in 1999 and currently serves as Senior Vice President of Quality Control, leading a global function that leverages strategic business partnerships and automation to provide back-up lab capabilities, protect the supply chain and optimize resources and lab capacity. He has held prior positions at Regeneron in Quality Control and Analytical Sciences, and prior to joining Regeneron, worked at Abbott Laboratories conducting diagnostic assay R&D, bio-process development and commercial assay kit manufacturing. He completed his post-doctoral studies at the University of Pennsylvania. He received his PhD in biochemistry from the University of Delaware and his MBA from the State University of New York at Albany.

Ron Wang, PhD

Senior Vice President, Quality Control

Ron Wang, PhD, joined Regeneron in 1999 and currently serves as Senior Vice President of Quality Control, leading a global function that leverages strategic business partnerships and automation to provide back-up lab capabilities, protect the supply chain and optimize resources and lab capacity. He has held prior positions at Regeneron in Quality Control and Analytical Sciences, and prior to joining Regeneron, worked at Abbott Laboratories conducting diagnostic assay R&D, bio-process development and commercial assay kit manufacturing. He completed his post-doctoral studies at the University of Pennsylvania. He received his PhD in biochemistry from the University of Delaware and his MBA from the State University of New York at Albany.

Close

P. Roy Vagelos, MD

P. Roy Vagelos, MD

P. Roy Vagelos, MD

Chairman of the Board; Retired Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.

P. Roy Vagelos, MD, has been Chairman of the Board of the company since January 1995. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck & Co., Inc. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985 and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos was on the Board of Directors of Theravance, Inc. through April 2010. Dr. Vagelos is a member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society.


Close

Bonnie L. Bassler, PhD

Bonnie L. Bassler, PhD

Bonnie L. Bassler, PhD

Chair, Department of Molecular Biology, and Squibb Professor in Molecular Biology, Princeton University

Bonnie L. Bassler, PhD, joined the board in 2016. She is currently the Chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University, and a Howard Hughes Medical Institute Investigator. Dr. Bassler has previously served as the President of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. She has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the Royal Society and the American Philosophical Society and has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award and the Shaw Prize for Life Science and Medicine. Dr. Bassler received her BSc from the University of California, Davis, and her PhD in Biochemistry from Johns Hopkins University. She served as a Postdoctoral Fellow and Research Scientist at the Agouron Institute in La Jolla, CA, before becoming a faculty member at Princeton University. Dr. Bassler served as a director of Sanofi from November 2014 to July 2016 and currently serves on the board of directors of Kaleido Biosciences, Inc.


Close

Michael S. Brown, MD

Michael S. Brown, MD

Michael S. Brown, MD

Regental Professor of Molecular Genetics and Internal Medicine, Director, Erik Jonsson Center for Molecular Genetics, The University of Texas Southwestern Medical Center at Dallas

Michael S. Brown, MD, has been a Director of the company since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine and the Director of the Erik Jonsson Center for Molecular Genetics and Human Disease at the University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Dr. Brown and Dr. Joseph Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988. Dr. Brown is a member of the National Academy of Sciences, the Institute of Medicine and Foreign Member of the Royal Society (London). Dr. Brown served as a member of the Board of Directors of Pfizer Inc. until April 2012.


Close

Tony Coles, MD

Tony Coles, MD

Tony Coles, MD

Executive Chairman and Chief Executive Officer, Cerevel Therapeutics

Dr. Coles is the Executive Chairman and Chief Executive Officer of Cerevel Therapeutics, a Bain-portfolio biotechnology company specializing in the development of new therapies for diseases of the central nervous system. Previously, Dr. Coles served as co-founder and Chief Executive Officer of Yumanity Therapeutics, LLC, from October 2014 until September 2019, and he continues to serve as the Executive Chair of the Board. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biopharmaceutical company. Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company, and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Dr. Coles has been a director of McKesson Corporation since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors.


Close

Joseph L. Goldstein, MD

Joseph L. Goldstein, MD

Joseph L. Goldstein, MD

Regental Professor and Chairman, Department of Molecular Genetics, The University of Texas Southwestern Center at Dallas

Joseph L. Goldstein, MD, has been a Director of the company since June 1991. Dr. Goldstein has been Professor of Medicine and Genetics and Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences, the National Academy of Medicine and the Royal Society of London. He also serves on the Boards of Trustees of The Rockefeller University and the Howard Hughes Medical Institute. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985.


Close

Christine A. Poon

Christine A. Poon

Christine A. Poon

Professor in the Department of Management and Human Resources at The Max M. Fisher College of Business, The Ohio State University

Christine A. Poon has been a director of the company since 2010. Ms. Poon is a Professor in the Department of Management and Human Resources at The Max M. Fisher College of Business at The Ohio State University, where she served as Dean and the John W. Berry, Sr. Chair in Business from 2009 to 2014. Prior to joining Fisher, Ms. Poon spent 30 years in the healthcare industry, most recently as vice chairman and worldwide chairman of pharmaceuticals at Johnson & Johnson, where she served on the company's Board of Directors and Executive Committee and was responsible for managing the pharmaceutical businesses of the company. Her areas of expertise include domestic and international business operations and sales and marketing. Prior to joining Johnson & Johnson, she spent 15 years at Bristol-Myers Squibb. Ms. Poon is on the Board of Directors of Prudential Financial, Inc. and the Supervisory Board of Royal Philips Electronics. She was named Woman of the Year by the Healthcare Businesswomen's Association in 2004, and named Business Leader of the Future by CNBC/Wall Street Journal in 2005.


Close

Arthur F. Ryan

Arthur F. Ryan

Arthur F. Ryan

Retired Chairman of the Board and Chief Executive Officer Prudential Financial, Inc.

Arthur F. Ryan has been a Director of the company since January 2003. In 2008, Mr. Ryan retired as the Chairman and Chief Executive Officer of Prudential Financial, Inc., one of the largest diversified financial institutions in the world. Prior to joining Prudential, Mr. Ryan served as President and Chief Operating Officer of Chase Manhattan Bank, where he also ran Chase's worldwide retail bank. From 2008 to 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc.


Close

Leonard S. Schleifer, MD, PhD

Leonard S. Schleifer, MD, PhD

Leonard S. Schleifer, MD, PhD

Co-Founder, President & Chief Executive Officer

Leonard S. Schleifer, MD, PhD, founded Regeneron in 1988, has been a Director and the company’s President and Chief Executive Officer since its inception. He served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Dr. Yancopoulos, has grown Regeneron from a tiny startup into a ~$50 billion market cap company, with a unique science-driven culture, successful drug discovery and development engine and seven FDA-approved medicines. Dr. Schleifer has been recognized as one of Barron’s Best CEOs and as an Ernst & Young Entrepreneur of the Year. He graduated from Cornell University and earned his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician, certified in Neurology by the American Board of Psychiatry and Neurology, and worked as a practicing neurologist before founding Regeneron.


Close

George L. Sing

George L. Sing

George L. Sing

Managing Director, Lancet Capital

George L. Sing has been a Director of the company since January 1988, during which time he also held the position of Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. Mr. Sing has also served as Chief Executive Officer of Stemnion, Inc., a biomedical company in the regenerative medicine field.


Close

Marc Tessier-Lavigne, PhD

Marc Tessier-Lavigne, PhD

Marc Tessier-Lavigne, PhD

President, Stanford University

Marc Tessier-Lavigne, PhD, has been a Director of the company since November 2011. Dr. Tessier-Lavigne was appointed as the President of Stanford University in September 2016. From March 2011 to August 2016, he served as the President of The Rockefeller University. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford and at the University of California, San Francisco. Dr. Tessier-Lavigne, a leader in the field of brain development, is a member of the National Academy of Sciences and its Institute of Medicine and a fellow of the Royal Societies of the United Kingdom and Canada. Dr. Tessier-Lavigne is a member of the Board of Directors of Denali Therapeutics Inc., and previously served on the board of directors of Pfizer Inc., Agios Pharmaceuticals, Inc. and Juno Therapeutics, Inc.


Close

George D. Yancopoulos, MD, PhD

George D. Yancopoulos, MD, PhD

George D. Yancopoulos, MD, PhD

President and Chief Scientific Officer

George D. Yancopoulos, MD, PhD, has built and managed Regeneron alongside Dr. Schleifer since 1989. He is currently President and Chief Scientific Officer and has served on the board since 2001. Dr. Yancopoulos, along with key members of his team, is the principal inventor of Regeneron’s seven FDA-approved drugs and foundational technologies, including the TRAP technology, VelociGene® and VelocImmune®. He has been named an Ernst & Young Entrepreneur of the Year and has been pivotal in creating the science-driven, collaborative and highly productive R&D culture at Regeneron. This unique environment has earned the company widespread recognition, including repeatedly being named one of the "most innovative companies in the world" by Forbes magazine. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004, he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos attended the Bronx High School of Science and received his MD and PhD from Columbia University.


Close

Huda Y. Zoghbi, MD

Huda Y. Zoghbi, MD

Huda Y. Zoghbi, MD

Professor, Departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience, Baylor College Director, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital

Huda Y. Zoghbi, MD, joined the board in 2016. Dr. Zoghbi is currently a professor in the departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine, the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital and an investigator of the Howard Hughes Medical Institute. She has been elected to the National Academy of Sciences, the Institute of Medicine and the American Association for the Advancement of Science, and has been awarded numerous recognitions for her work, including the Pearl Meister Greengard Prize, the March of Dimes Prize in Developmental Biology and the Vanderbilt Prize in Biomedical Science. Dr. Zoghbi earned her BSc from the American University of Beirut, received her MD from Meharry Medical College in Nashville, TN, and completed her pediatrics residency and a joint residency in neurology and pediatric neurology at Baylor College of Medicine, where she then pursued postdoctoral research training in molecular genetics.


Close
Back to top